Carles Servat-Codony
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer.
Journal: Translational lung cancer research
Published: November 19, 2020
Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer.
Journal: Translational lung cancer research
Published: November 19, 2019
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.
Journal: Translational lung cancer research
Published: September 27, 2019
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Journal: Cell communication and signaling : CCS
Published: July 31, 2019
Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).
Journal: International journal of biological sciences
Published: January 21, 2019
Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.
Journal: Translational lung cancer research
Published: November 06, 2018
Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.
Journal: Clinical lung cancer
Published: November 05, 2018
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
Journal: Nature communications
Published: August 20, 2018
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.
Journal: Therapeutic advances in medical oncology
Published: November 21, 2017
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Journal: Oncotarget
Published: March 07, 2017
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Journal: Nature communications
Published: October 30, 2016
Last Updated: 09/26/2026